Investors Purchase High Volume of Put Options on Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics Inc (NASDAQ:HRTX) was the target of unusually large options trading activity on Wednesday. Stock traders purchased 1,188 put options on the company. This represents an increase of 1,700% compared to the average daily volume of 66 put options.

A number of research firms recently issued reports on HRTX. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Stifel Nicolaus reiterated a “buy” rating and set a $38.00 price objective on shares of Heron Therapeutics in a research report on Monday, August 5th. Northland Securities reiterated a “buy” rating and set a $55.00 price objective on shares of Heron Therapeutics in a research report on Monday, August 5th. BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, Evercore ISI reiterated a “buy” rating and set a $75.00 price objective on shares of Heron Therapeutics in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. Heron Therapeutics presently has an average rating of “Hold” and a consensus target price of $52.67.

HRTX stock traded down $0.13 during trading on Thursday, reaching $20.61. 20,726 shares of the company were exchanged, compared to its average volume of 947,795. The company has a 50-day moving average of $17.75 and a two-hundred day moving average of $20.27. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -8.42 and a beta of 1.47. Heron Therapeutics has a twelve month low of $15.68 and a twelve month high of $37.25. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.01 and a quick ratio of 3.70.



Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. The firm had revenue of $36.66 million for the quarter, compared to analyst estimates of $31.04 million. On average, analysts forecast that Heron Therapeutics will post -2.73 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of HRTX. Meadow Creek Investment Management LLC bought a new stake in Heron Therapeutics during the 2nd quarter worth approximately $27,000. Lindbrook Capital LLC bought a new stake in Heron Therapeutics during the 2nd quarter worth approximately $37,000. Parallel Advisors LLC grew its holdings in Heron Therapeutics by 247.4% during the 1st quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 1,200 shares during the last quarter. US Bancorp DE grew its holdings in Heron Therapeutics by 75.6% during the 2nd quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 1,769 shares during the last quarter. Finally, Tiverton Asset Management LLC bought a new stake in Heron Therapeutics during the 2nd quarter worth approximately $101,000.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Story: Trading Stocks – What are percentage gainers?

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.